NCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT06163040 2025-07-31
A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT03989414 2024-11-29
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Celgene
Phase 1/2 Active not recruiting
NCT03651128 2022-12-15
KarMMa-3
Celgene
Phase 3 Active not recruiting